Dornase Alfa as a Potential Treatment Option for SARS-CoV-2: In Vitro Insights

Read full text Summarise with VIRAT
Authors: Derya Dilek Kançağı, Cihan Taştan, Kevser Buse Karadeniz, Selen Abanuz, Didem Akyoney, Yaren Buyukcolak, Sezer Akyoney, Gözde Sır Karakuş, Bulut Yurtsever, Koray Yalçın, İsmail Tuncer Değim, Ercüment Ovalı
Cited by: 0
References: 1

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

The potential use of dornase alfa (DA) for managing severe acute respiratory syndrome coronavirus 2 infection has been a topic of frequent discussion; however, its underlying mechanism of effectiveness remains insufficiently explored. By shedding light on the mechanisms involved, this research endeavors to contribute to the broader understanding of DA's suitability as a potential treatment option for SARS-CoV-2 infection. In this study, the effects of DA on SARS-CoV-2 were investigated to determine the change in the level of viral cytotoxicity, viral RNA fragmentation, spike blockage, in vitro Th1/Th2 cytokine ratio of viral peptide stimulated lymphocytes and netosis Neutrophil extracellular traps formation. The analysis demonstrated that DA decreased the viral cytotoxicity at 30U (p

Fields of Study & Subjects

SARS-CoV-2 and COVID-19 Research COVID-19 Clinical Research Studies SARS-CoV-2 detection and testing

Publication details

Journal / source
Fabad Journal of Pharmaceutical Sciences
Volume
51
Issue
1
Pages
175–188
Publication date
31 March 2026
Language
TR